<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750268</url>
  </required_header>
  <id_info>
    <org_study_id>W81XWH-11-2-0145</org_study_id>
    <nct_id>NCT01750268</nct_id>
  </id_info>
  <brief_title>Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI</brief_title>
  <acronym>VAT</acronym>
  <official_title>Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern California Institute of Research and Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Francisco Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed project is to improve the treatment of veterans with co-occurring&#xD;
      traumatic brain injury (TBI) and hazardous or harmful alcohol use. The PI and coinvestigators&#xD;
      will conduct a pilot controlled clinical trial of topiramate for the treatment of these&#xD;
      co-occurring disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Number of Drinking Days Per Week as Assessed by the Timeline Followback (TLFB)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Using a calendar, participants provide retrospective estimates of daily drinking over a specified period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in TBI Symptom Severity as Assessed by the Neurobehavioral Symptom Inventory (NSI)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Participants indicate the extent to which each of the 22 symptoms has disturbed them in the previous 2 weeks on a 5-item scale (0-none to 4-severe). The NSI total score is the sum of severity ratings of the symptoms. The scores are summed to yield a total score ranging from 0 to 88, where the higher the point value, the greater (more severe) the symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Alcohol Use as Assessed by the Timeline Followback (TLFB)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Using a calendar, participants provide retrospective estimates of daily drinking over a specified period.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Traumatic Brain Injury (TBI)</condition>
  <condition>Hazardous and Harmful Alcohol Use</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate capsules daily - up to 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules daily - up 300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medical Management Counseling</intervention_name>
    <description>Brief alcohol and medication counseling</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Topiramate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Experimental medication</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male and female veterans.&#xD;
&#xD;
          2. Ages 18 to 65 (inclusive).&#xD;
&#xD;
          3. TBI: a history of mild traumatic brain injury, as defined by American Congress of&#xD;
             Rehabilitation Medicine (ACRM) and VA, in the chronic, stable phase of recovery (&gt;6&#xD;
             months from injury). The ACRM defines mild TBI as a traumatically-induced&#xD;
             physiological disruption of brain function as demonstrated by at least one of the&#xD;
             following:&#xD;
&#xD;
        3.a. loss of consciousness of up to 30 minutes;&#xD;
&#xD;
        3.b. any loss of memory for events immediately before or after the event;&#xD;
&#xD;
        3.c. any alteration in mental state at the time of the event, for example feeling dazed,&#xD;
        disoriented, or confused; and&#xD;
&#xD;
        3.d. a focal neurological deficit or deficits that may or may not have been transient, for&#xD;
        example loss of coordination, speech difficulties, or double vision. ACRM's definition&#xD;
        further specifies that a person may be designated as having a mild TBI only if the severity&#xD;
        of the injury does not include a loss of consciousness that lasted longer than 30 minutes,&#xD;
        and post-traumatic amnesia lasting longer than 24 hours.&#xD;
&#xD;
        Rationale:&#xD;
&#xD;
          1. This is the most common description of patients currently served by our VA facilities.&#xD;
&#xD;
          2. Studies at this stable phase will facilitate detection of otherwise subtle changes as&#xD;
             findings are less likely to be confounded by 'spontaneous' recovery.&#xD;
&#xD;
        4. Current (past month) hazardous alcohol use or harmful alcohol use.&#xD;
&#xD;
        4.a. Hazardous use is drinking that must meet criteria for &quot;at-risk&quot; or &quot;heavy&quot; drinking by&#xD;
        National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria: Subjects must report&#xD;
        current (past 30 day) &quot;at-risk&quot; or &quot;heavy&quot; drinking on an average weekly basis, consisting&#xD;
        of an average of 15 or more standard drinks per week for men and 8 or more standard drinks&#xD;
        per week for women during the 30 days prior to Screening Visit 1 as measured by the Alcohol&#xD;
        Timeline Followback (TLFB) method.&#xD;
&#xD;
        4.b. Harmful use is drinking behavior that meets Diagnostic and Statistical Manual (DSM)-IV&#xD;
        diagnostic criteria for an Alcohol Use Disorder (Alcohol Dependence or Alcohol Abuse).&#xD;
&#xD;
        5. Subjects must express a desire to reduce or stop alcohol use.&#xD;
&#xD;
        6. Female subjects must have a negative urine pregnancy test and must be either&#xD;
        postmenopausal for at least 1 year or practicing an effective method of birth control&#xD;
        (e.g., surgically sterile, spermicide with barrier, male partner sterilization; or absent&#xD;
        and agrees to continue abstinence or to use an acceptable method of contraception, as&#xD;
        listed above, should sexual activity commence).&#xD;
&#xD;
        7. Subjects must have a Breath Alcohol Concentration (BAC) of less than 0.02% when signing&#xD;
        the informed consent form.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Psychotic disorders, bipolar disorders, dementia, or other psychiatric disorders&#xD;
             judged to be unstable.&#xD;
&#xD;
          2. Subjects known to have clinically significant unstable medical conditions, including&#xD;
             but not limited to: Clinically significant renal disease and/or impaired renal&#xD;
             function as defined by clinically significant elevation of blood urea nitrogen (BUN)&#xD;
             or creatinine or an estimated creatinine clearance of &lt; 60 mL/min; AST and/or ALT &gt; 5&#xD;
             times the upper limit of the normal range and/or a serum bilirubin &gt; 2 times the upper&#xD;
             limit of normal.&#xD;
&#xD;
          3. History of glaucoma.&#xD;
&#xD;
          4. History of kidney stones.&#xD;
&#xD;
          5. Concurrent participation in another alcohol treatment study or any study involving&#xD;
             medications.&#xD;
&#xD;
          6. Female patients who are pregnant or lactating.&#xD;
&#xD;
          7. Topiramate use in the past week prior to study entry.&#xD;
&#xD;
          8. Use of medications for alcohol dependence (disulfiram, naltrexone, or acamprosate)&#xD;
             within the past week.&#xD;
&#xD;
          9. Needing acute medical detoxification from alcohol based on a score of 12 or more on&#xD;
             the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD).&#xD;
&#xD;
         10. Subjects who are legally mandated to participate in an alcohol treatment program.&#xD;
&#xD;
         11. Subjects who have had a suicide attempt in the past 6 months or suicidal ideation,&#xD;
             with intent, in the 30 days prior to enrollment.&#xD;
&#xD;
         12. Subjects who have previously been treated with topiramate for any reason and&#xD;
             discontinued treatment due to an adverse event or due to a hypersensitivity reaction&#xD;
             to topiramate.&#xD;
&#xD;
         13. Subjects with seizure disorders.&#xD;
&#xD;
         14. Subjects currently being treated with another anticonvulsant.&#xD;
&#xD;
         15. Subjects who in the opinion of the investigator should not be enrolled in the study&#xD;
             because of the precautions, warnings or contraindications outlined in the topiramate&#xD;
             package insert.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven L. Batki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pennington DL, Bielenberg J, Lasher B, Herbst E, Abrams G, Novakovic-Agopian T, Batki SL. A randomized pilot trial of topiramate for alcohol use disorder in veterans with traumatic brain injury: Effects on alcohol use, cognition, and post-concussive symptoms. Drug Alcohol Depend. 2020 Sep 1;214:108149. doi: 10.1016/j.drugalcdep.2020.108149. Epub 2020 Jul 2.</citation>
    <PMID>32712569</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <results_first_submitted>September 26, 2019</results_first_submitted>
  <results_first_submitted_qc>September 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TBI</keyword>
  <keyword>hazardous and harmful alcohol use</keyword>
  <keyword>veterans</keyword>
  <keyword>co-occurring disorders</keyword>
  <keyword>pharmacotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Topiramate</title>
          <description>Topiramate capsules daily - up to 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Topiramate: Experimental medication</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo capsules daily - up 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Placebo: Placebo comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topiramate</title>
          <description>Topiramate capsules daily - up to 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Topiramate: Experimental medication</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo capsules daily - up 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Placebo: Placebo comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="13.5"/>
                    <measurement group_id="B2" value="48.5" spread="14.0"/>
                    <measurement group_id="B3" value="46.6" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Number of Drinking Days Per Week as Assessed by the Timeline Followback (TLFB)</title>
        <description>Using a calendar, participants provide retrospective estimates of daily drinking over a specified period.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate</title>
            <description>Topiramate capsules daily - up to 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Topiramate: Experimental medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules daily - up 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number of Drinking Days Per Week as Assessed by the Timeline Followback (TLFB)</title>
          <description>Using a calendar, participants provide retrospective estimates of daily drinking over a specified period.</description>
          <units>Drinking Days per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.8"/>
                    <measurement group_id="O2" value="1.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TBI Symptom Severity as Assessed by the Neurobehavioral Symptom Inventory (NSI)</title>
        <description>Participants indicate the extent to which each of the 22 symptoms has disturbed them in the previous 2 weeks on a 5-item scale (0-none to 4-severe). The NSI total score is the sum of severity ratings of the symptoms. The scores are summed to yield a total score ranging from 0 to 88, where the higher the point value, the greater (more severe) the symptoms.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate</title>
            <description>Topiramate capsules daily - up to 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Topiramate: Experimental medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules daily - up 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TBI Symptom Severity as Assessed by the Neurobehavioral Symptom Inventory (NSI)</title>
          <description>Participants indicate the extent to which each of the 22 symptoms has disturbed them in the previous 2 weeks on a 5-item scale (0-none to 4-severe). The NSI total score is the sum of severity ratings of the symptoms. The scores are summed to yield a total score ranging from 0 to 88, where the higher the point value, the greater (more severe) the symptoms.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="13.1"/>
                    <measurement group_id="O2" value="19.3" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Alcohol Use as Assessed by the Timeline Followback (TLFB)</title>
        <description>Using a calendar, participants provide retrospective estimates of daily drinking over a specified period.</description>
        <time_frame>Baseline to Week 12</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment through study completion, an average of 12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Topiramate</title>
          <description>Topiramate capsules daily - up to 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Topiramate: Experimental medication</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo capsules daily - up 300 mg&#xD;
Medical Management Counseling: Brief alcohol and medication counseling&#xD;
Placebo: Placebo comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Inpatient medical hospitalization for an episode of chest pain in the context of cocaine use</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inpatient medical hospitalization for planned distal pancreatectomy and splenectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Voluntary psych inpatient admission due to homicidal ideation in the context of heavy cocaine use</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Inpatient medical hospitalization due to alcohol withdrawal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal vision</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness and tingling</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Change in sense of taste</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Difficulty with concentration and attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Difficulty with memory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Slow thinking</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Language problems</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Suicidal thoughts and actions</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven L. Batki, MD</name_or_title>
      <organization>San Francisco VA Health Care System/University of California, San Francisco</organization>
      <phone>415-221-4810 ext 23671</phone>
      <email>steven.batki@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

